The STRIVE and ENVISION phase 3 clinical trials showed ivacaftor—the first CFTR potentiator—markedly improved lung function, nutritional status, and patient-reported respiratory symptoms in persons with CF having the G551D-CFTR mutation (Table 2). The gene discussed is CFTR; the disease is cystic fibrosis.